Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells $131,033.28 in Stock

Health Catalyst, Inc. (NASDAQ:HCATGet Rating) COO Paul Horstmeier sold 5,208 shares of Health Catalyst stock in a transaction that occurred on Tuesday, April 12th. The stock was sold at an average price of $25.16, for a total value of $131,033.28. Following the completion of the transaction, the chief operating officer now directly owns 180,316 shares in the company, valued at $4,536,750.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Paul Horstmeier also recently made the following trade(s):

  • On Wednesday, March 9th, Paul Horstmeier sold 23,209 shares of Health Catalyst stock. The stock was sold at an average price of $25.30, for a total value of $587,187.70.
  • On Monday, February 7th, Paul Horstmeier sold 10,750 shares of Health Catalyst stock. The shares were sold at an average price of $29.10, for a total value of $312,825.00.

Health Catalyst stock opened at $23.81 on Friday. The firm has a market cap of $1.24 billion, a P/E ratio of -7.42 and a beta of 0.89. Health Catalyst, Inc. has a 52 week low of $20.39 and a 52 week high of $59.50. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.46 and a current ratio of 5.46. The business’s fifty day moving average is $26.06 and its two-hundred day moving average is $36.43.

Health Catalyst (NASDAQ:HCATGet Rating) last released its earnings results on Tuesday, March 1st. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.02. The company had revenue of $64.72 million during the quarter, compared to the consensus estimate of $63.17 million. Health Catalyst had a negative return on equity of 21.30% and a negative net margin of 63.33%. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.41) earnings per share. On average, equities research analysts predict that Health Catalyst, Inc. will post -1.8 earnings per share for the current year.

HCAT has been the topic of several recent analyst reports. Raymond James decreased their price target on Health Catalyst from $70.00 to $40.00 and set a “strong-buy” rating on the stock in a research note on Friday, March 4th. The Goldman Sachs Group initiated coverage on Health Catalyst in a research note on Friday, February 11th. They issued a “buy” rating and a $48.00 price target on the stock. Canaccord Genuity Group decreased their price target on Health Catalyst from $62.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, March 2nd. Royal Bank of Canada decreased their price target on Health Catalyst from $66.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 2nd. Finally, Jefferies Financial Group raised Health Catalyst from a “hold” rating to a “buy” rating and decreased their price target for the company from $31.00 to $28.00 in a research note on Thursday, March 17th. One equities research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $44.29.

Several hedge funds have recently added to or reduced their stakes in HCAT. UMB Bank N A MO bought a new stake in shares of Health Catalyst during the fourth quarter worth $30,000. Sageworth Trust Co of South Dakota bought a new stake in shares of Health Catalyst during the fourth quarter worth $61,000. Advisor Group Holdings Inc. raised its position in shares of Health Catalyst by 27.3% during the third quarter. Advisor Group Holdings Inc. now owns 1,466 shares of the company’s stock worth $73,000 after acquiring an additional 314 shares during the last quarter. O Shaughnessy Asset Management LLC raised its position in shares of Health Catalyst by 23.3% during the third quarter. O Shaughnessy Asset Management LLC now owns 2,452 shares of the company’s stock worth $123,000 after acquiring an additional 463 shares during the last quarter. Finally, Strs Ohio raised its position in shares of Health Catalyst by 50.0% during the third quarter. Strs Ohio now owns 3,300 shares of the company’s stock worth $165,000 after acquiring an additional 1,100 shares during the last quarter.

About Health Catalyst (Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its solutions include a cloud-based data platform, analytics software, and professional services. The company was formerly known as HQC Holdings, Inc and changed its name to Health Catalyst, Inc in March 2017.

Further Reading

Insider Buying and Selling by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.